Search

Displaying results 3251 - 3260 of 10000 in total
  1. Drug

    Moclobemide

    go.drugbank.com/drugs/DB01171
    ApprovedInvestigational

    Most meta-analyses and most studies indicate that in the acute management of depression, moclobemide is more efficacious than placebo medication and similarly efficacious as tricyclic antidepressants ( … A reversible monoamine oxidase inhibitor (MAOI) selective for isoform A (RIMA) used to treat major depressive disorder.

    Synonyms: 4-Chlor-N-(2-morpholinoethyl)benzamid, p-Chloro-N-(2-morpholinoethyl)benzamideCategories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Monoamine Oxidase A Inhibitors
  2. Drug

    CX501

    go.drugbank.com/drugs/DB05174
    Investigational

    Cx501 is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction of the joints, fusion of fingers and toes, contraction of the mouth membranes and narrowing of … It is developed by Cellerix and is in phase I of clinical trials.

  3. Drug

    Ciclesonide

    go.drugbank.com/drugs/DB01410
    ApprovedInvestigational

    Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.

  4. Drug

    NS-2359

    go.drugbank.com/drugs/DB05805
    Investigational

    This mode of action is expected to produce an optimal reduction in all disease symptoms and the possibility of an earlier onset of action compared to antidepressants already on the market. … NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression.

  5. Drug

    Sovateltide

    go.drugbank.com/drugs/DB06138
    Investigational

    It is being developed as an adjunct to chemotherapy. … SPI-1620 is an endothelin B receptor agonist. In animal models SPI-1620 selectively and transiently increases tumor blood flow allowing increased delivery of anticancer agents to the tumor.

  6. Drug

    Dermatophagoides farinae

    go.drugbank.com/drugs/DB10400
    ApprovedInvestigational

    This combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue as a treatment for dust mite allergies.

  7. Drug

    Dermatophagoides pteronyssinus

    go.drugbank.com/drugs/DB10401
    ApprovedInvestigational

    This combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue as a treatment for dust mite allergies.

  8. Drug

    Risdiplam

    go.drugbank.com/drugs/DB15305
    ApprovedInvestigational

    Risdiplam is an orally bioavailable mRNA splicing modifier used for the treatment of spinal muscular atrophy (SMA). … [L15351,A216871] Risdiplam was approved by the FDA in August 2020 for the treatment of spinal muscular atrophy (SMA).

  9. Drug

    Benmoxin

    go.drugbank.com/drugs/DB09246
    ApprovedWithdrawn

    Benmoxin is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine class. It was first synthesized in 1967 and rapidly used in Europe as an antidepressant.

  10. Drug

    Tiaprofenic acid

    go.drugbank.com/drugs/DB01600
    Approved

    Tiaprofenic acid is a non-steroidal anti-inflammatory drug employed in the treatment of pain, particularly arthritis pain.